{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:14:15Z","timestamp":1791609255412,"version":"4.3.4"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The German psoriasis registry PsoBest records the long\u2010term efficacy, safety, patient benefit and treatment regimens of psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Patients with moderate or severe psoriasis are included in PsoBest when treatment with a conventional systemic agent or biologic is started for the first time. Observation time is five years. Standardized physician and patient case report forms are obtained every three to six months. Baseline data of patients included by 31 December 2012 are presented and compared to the national health care study PsoHealth 2007 (n = 2,009).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>602 dermatology practices and clinics have been registered and 199 have recruited n = 2,556 patients (63 % by practices, 37 % by clinics). Initially, n = 808 received biologics (316 adalimumab, 34 efalizumab, 209 etanercept, 75 infliximab, 22 golimumab, 152 ustekinumab) and n = 1,651 conventional systemic therapy (928 fumaric acid esters, 518 methotrexate, 161 cyclosporine A, 191 other drugs or UV treatment). Compared to PsoHealth, patients in PsoBest had on average a higher disease severity (PASI 14.7 vs. 10.1; DLQI 11.0 vs. 7.5; EQ\u20105D VAS 54.0 vs. 64.5), shorter disease duration (18.2 vs. 21.3 yrs.), lower age (47.3 vs. 51.5), higher rates of psoriatic arthritis (20.5 vs. 19.1 %) and nail psoriasis (55.0 vs. 35.6 %). On average patients receiving biologics were younger, more often male and had higher disease severity and comorbidity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients in PsoBest represent patients with a high burden of disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.12233","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T08:35:17Z","timestamp":1389083717000},"page":"48-57","source":"Crossref","is-referenced-by-count":43,"title":["German psoriasis registry PsoBest: objectives, methodology and baseline data"],"prefix":"10.1111","volume":"12","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[{"name":"IVDP \u2013 Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Spehr","sequence":"additional","affiliation":[{"name":"IVDP \u2013 Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Radtke","sequence":"additional","affiliation":[{"name":"IVDP \u2013 Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf\u2010Henning","family":"Boehncke","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Geneva University Hospital and Department of Pathology and Immunology Medical Faculty of the University of Geneva  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luger","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of M\u00fcnster  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Psoriasis Center, Department of Dermatology Venereology and Allergology University Hospital Schleswig\u2010Holstein  Campus Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reusch","sequence":"additional","affiliation":[{"name":"Dermatology Group Office am Tibarg  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Str\u00f6mer","sequence":"additional","affiliation":[{"name":"Group Office for Dermatology and Allergology  M\u00f6nchengladbach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Wozel","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Carl Gustav Carus  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph v.","family":"Kiedrowski","sequence":"additional","affiliation":[{"name":"Dermatology Office Dr. Ralph von Kiedrowski  Selters\/Westerwald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J.","family":"Rustenbach","sequence":"additional","affiliation":[{"name":"IVDP \u2013 Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Purwins","sequence":"additional","affiliation":[{"name":"IVDP \u2013 Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Dermatologikum  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Registries for Evaluating Patient Outcomes: A User's Guide","author":"Glicklich R","year":"2010"},{"key":"e_1_2_9_3_1","first-page":"824","article-title":"[Memorandum registry for health services research]","volume":"72","author":"M\u00fcller D","year":"2010","journal-title":"Gesundheitswesen"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-010-2080-y"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22193"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_9_7_1","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).Guide on Methodological Standards in Pharmacoepidemiology [Internet]. cited: 2013 October 31. Available from:http:\/\/encepp.eu\/standards_and_guidances."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"e_1_2_9_9_1","unstructured":"AgencyEM.Not for Guidance on Clinical Safety Data Management.2006."},{"key":"e_1_2_9_10_1","unstructured":"AgencyEM.Volume 9A of The Rules Governing Medicinal Products in the European Union \u2013 Guidelines on Pharmacovigilance for Medicinal Products for Human Use.2008."},{"key":"e_1_2_9_11_1","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. European Medicines Agency 2012."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04576.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2009.07079.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.3.199"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338572"},{"key":"e_1_2_9_16_1","unstructured":"PsoNet.PsoNet. European Registry of Psoriasis. Centro Studi GISED. [Internet]. cited: 2013 October 31. Available from:http:\/\/www.psonet.eu."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000096196"},{"key":"e_1_2_9_18_1","first-page":"S1","article-title":"German S3\u2010guidelines on the treatment of psoriasis vulgaris update 2011","volume":"9","author":"Nast A","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000183757"},{"key":"e_1_2_9_21_1","volume-title":"Medical Dictionary for Regulatory Activities terminology is the international medical terminology developed under the auspices of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1471"},{"key":"e_1_2_9_23_1","unstructured":"(DAE) AEMdDAfE.Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP)2004."},{"key":"e_1_2_9_24_1","unstructured":"PsoBest.Das deutsche Psoriasis\u2010Register. [Internet]. cited: 2013 October 31. Available from:http:\/\/www.psobest.de."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06807.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2012.08071.x_suppl"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03462.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1684\/ejd.2012.1740","article-title":"Quality of psoriasis care from the patients\u2019 perspective \u2013 Results of the national health care study PsoReal","volume":"22","author":"Langenbruch A","year":"2012","journal-title":"Eur J Dermatol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000119415"},{"key":"e_1_2_9_31_1","first-page":"1210","article-title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease\u2010based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp KA","year":"2012","journal-title":"J Drugs Dermatol"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.12233","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.12233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:01:23Z","timestamp":1696345283000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.12233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/ddg.12233"],"URL":"https:\/\/doi.org\/10.1111\/ddg.12233","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}